Vir Biotechnology, Inc. is making strategic changes to focus on high-value programs, resulting in a reduction of workforce and closure of certain facilities, with estimated charges of $30-40 million and annual cost savings of at least $40 million. The company reported $1.7 billion in cash and investments in Q3 2023.